-
Mashup Score: 29Natural history and progression of metabolic dysfunction-associated steatotic liver disease - 28 day(s) ago
The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. A minority of patients develop inflammation and risk progressive fibrosis that can result in cirrhosis. Progression to cirrhosis occurs in 3–5% of patients and often takes more than 20 years. This narrative review presents an update on the natural history of MASLD, discussing studies and risk estimates for progression to severe outcomes, such as decompensated cirrhosis or hepatocellular carcinoma.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 32The Lancet Gastroenterology and Hepatology: Homepage - 3 month(s) ago
Discover articles from The Lancet Gastroenterology & Hepatology, providing a clear, independent perspective about the clinical advances and practice-changing research shaping your specialty globally
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet-
Our latest issue is now live at https://t.co/bK6A0hWoAC! Content includes food insecurity, the global epidemiology of #HBV, management of malignant bowel obstruction, psychological therapy for #IBD, #NASH drug development + more #GITwitter #LiverTwitter #MedTwitter https://t.co/AHIzKdjS8q
-
-
Mashup Score: 32The Lancet Gastroenterology and Hepatology: Homepage - 3 month(s) ago
Discover articles from The Lancet Gastroenterology & Hepatology, providing a clear, independent perspective about the clinical advances and practice-changing research shaping your specialty globally
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet-
Our latest issue is now live at https://t.co/bK6A0hWoAC! Content includes food insecurity, the global epidemiology of #HBV, management of malignant bowel obstruction, psychological therapy for #IBD, #NASH drug development + more #GITwitter #LiverTwitter #MedTwitter https://t.co/AHIzKdjS8q
-
-
Mashup Score: 41Pathogens don't respect politicians: US federal disruption poses a new threat to global public health - 3 month(s) ago
We are facing a new threat to global health.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet-
New Correspondence - Wang et al - Pathogens don’t respect politicians: US federal disruption poses a new threat to global public health https://t.co/xiVYL36yqY #MedTwitter #USAID #PEPFAR #NIH https://t.co/lV8ZMJtUAq
-
-
Mashup Score: 30Overcoming the challenges of overtreating and undertreating inflammatory bowel disease - 3 month(s) ago
Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding therapeutic armamentarium and the increasingly ambitious treatment targets have led to an increased use of advanced therapies and better outcomes. Nevertheless, many patients remain suboptimally treated and are at risk of disease progression, hospital admission, and surgery, even when advanced therapies are cycled, escalated, or combined. Conversely, IBD can also be characterised by an indolent disease course.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet-
New Review - Temido et al - Overcoming the challenges of overtreating and undertreating inflammatory bowel disease https://t.co/YYklTyC6hk #GITwitter https://t.co/LiwB7F988O
-
-
Mashup Score: 29
The results of this interim analysis suggest that early treatment with tenofovir alafenamide reduces the risk of liver-related serious adverse events compared with observation in adults with non-cirrhotic chronic hepatitis B and moderate or high viraemia but normal or mildly elevated ALT concentrations. Although these findings await confirmation in planned future analyses, they suggest that existing guidelines could be expanded to allow early antiviral therapy in patients with a moderate or high HBV viral load, irrespective of ALT concentrations.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet-
New research - Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia: interim results from the ATTENTION RCT https://t.co/UR77oV2DIw #LiverTwitter #MedTwitter https://t.co/qApXSjIlbZ
-
-
Mashup Score: 217
Although underpowered and incomplete, Neo-AEGIS provides the largest comprehensive randomised dataset for patients with adenocarcinoma of the oesophagus and oesophagogastric junction treated with perioperative chemotherapy (predominantly the modified MAGIC regimen), and CROSS trimodality therapy, and reports similar 3-year survival and no major differences in operative and health-related quality of life outcomes. We suggest that these data support continued clinical equipoise.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet-
New research - Reynolds et al - Trimodality therapy vs perioperative chemotherapy for locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS phase 3 trial https://t.co/EdgLoCFAWw #OncTwitter #GITwitter #EsoCSM https://t.co/BN5X9IvM4A
-
-
Mashup Score: 39
Durvalumab plus bevacizumab plus TACE has the potential to set a new standard of care. With additional follow-up of the EMERALD-1 study, future analyses, including the final overall survival data and patient-reported outcomes, will help to further characterise the potential clinical benefits of durvalumab plus bevacizumab plus TACE in hepatocellular carcinoma amenable to embolisation.
Source: www.thelancet.comCategories: General Medicine News, GastroenterologyTweet-
New research @TheLancet - Durvalumab with or without bevacizumab with TACE in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study https://t.co/34sncX89xY #LiverTwitter #OncTwitter @OncoAlert #GITwitter https://t.co/wFLEqNlDda
-
-
Mashup Score: 0
Treatment failure rate at 1 year reached 34% with antibiotics versus 7% with appendectomy
Source: www.medpagetoday.comCategories: General Medicine News, GastroenterologyTweet-
Antibiotics Inferior to Appendectomy for Uncomplicated Appendicitis in Kids https://t.co/u4yiqXtpBp, via @medpagetoday #GastroSky #SoMe4Surg
-
-
Mashup Score: 0
Treatment failure rate at 1 year reached 34% with antibiotics versus 7% with appendectomy
Source: www.medpagetoday.comCategories: General Medicine News, GastroenterologyTweet-
Antibiotics Inferior to Appendectomy for Uncomplicated Appendicitis in Kids https://t.co/u4yiqXtpBp, via @medpagetoday #GastroSky #SoMe4Surg
-
RT @HannesHagstrom: Happy to share our narrative review of the natural history of MASLD in @LancetGastroHep Link: https://t.co/OrA2OKl1na…